dupilumab
FDA Expands Dupilumab EoE Indication to Children as Young as 1 Year
The FDA expanded the indications for dupilumab (Dupixent, Regeneron/Sanofi) to include treatment of children with ...
JANUARY 26, 2024
More Data Support Dupilumab for Severe EoE
Dupilumab improves eosinophilic esophagitis, with benefits sustained to 52 weeks, according to updated analyses of ...
MARCH 3, 2023
Exploring Use of Dupilumab for Patients With EoE
The clinical trial data supporting dupilumab for the treatment of eosinophilic esophagitis were very strong in the ...
JULY 29, 2022
Dupilumab Reduces Eosinophilic Esophagitis Symptoms in New Trial
Dupilumab decreased esophageal inflammation and may improve the ability of patients with eosinophilic esophagitis ...
JULY 2, 2022
FDA Expands Dupilumab Indication to EoE
The FDA has approved dupilumab to treat eosinophilic esophagitis in patients 12 years and older weighing more than ...
MAY 20, 2022
